🔗 Share this article

While the United States proceeds with sweeping revisions to its vaccine guidelines, one figure appears unexpectedly: Tracy Beth Høeg, a US-based sports physician and public health researcher who initially gained attention by casting doubt on coronavirus vaccinations in the pandemic and has zeroed in on possible deaths after COVID-19 vaccination in her short position at the FDA.

Planned Shifts to Childhood Immunization Program

Agency leaders had intended to unveil sweeping changes to the pediatric vaccine schedule earlier this month, synchronizing the US with Denmark’s vaccine program, sources say – a significant shift that would put the US out of alignment with a large portion of the global community with insufficient data for benefit. This reveal has been pushed back until the coming year.

In place of Vinay Prasad, Tracy Beth Høeg is scheduled to present at the meeting. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth individual to head the division this calendar year.

A New Direction at the FDA

This interim role may indicate a closer partnership between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it signals a greater focus upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has often pushed for halting specific pediatric vaccine recommendations in the US so as to align more in line with the Danish model, a nation with nationalized medicine and a number of inhabitants roughly the population of the state of Wisconsin.

In her initial comments, she has continued to focus on immunizations – traditionally the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Questions Over Expertise

The appointee has no obvious background in pharmaceutical research, approval processes or administrative roles, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the FDA chief and the vaccine center since March.

“She appears not to have the necessary background” for leading the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in leading a major agency. She has no expertise in drug approvals.”

Previous heads of CBER would “grasp laws and regulations and the science of medication creation”, noted a former acting FDA commissioner. “Objectively, she has not acquired the sort of resume that previous people who ran CBER have had.”

The drug center has an immense portfolio at the agency, the former commissioner emphasized.

“Everybody just zeroes in on the innovative therapies, but the generic program authorizes thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, non-prescription drug unit and so forth, and each of these need to be managed,” Woodcock explained. “The responsibility you neglect, that is the part that I always told people is going to cause problems.”

There is also, a major management aspect to the position, which oversees more than 5,000 personnel. “It’s a massive leadership role, if you perform it correctly,” the former official added.

Official Statement and Disputed Initiatives

In response to concerns about Høeg’s credentials and whether this appointment signifies greater collaboration among regulatory chiefs on vaccines, a representative stated that the “questions rely on inaccurate premises”.

“Her resume aligns with the duties of her position,” the representative said, noting the months Dr. Høeg spent advising the agency head on “medication safety and oversight research, including computational safety modeling and immunization monitoring”.

In her interim role, Høeg assumes responsibility for the commissioner’s controversial fast-track approval initiative, a contentious expedited therapy clearance system that reportedly worried her preceding directors. “By what process are these medications being picked for this voucher program? Who takes the calls?” Dr. Howard questioned. “There is a lot of confidentiality occurring at the agency right now.”

Overall, he stated, “the agency appears to be shifting towards less stringent rules of most medications, with the exception of shots.”

Established Past Work on Immunizations

Regarding vaccines, Høeg has a clearer, if concerning, history, some experts observe. She authored a study using non-validated public submissions to determine the rate of myocarditis following Covid immunization. She advised the Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to imply Covid vaccinations are riskier than they are.

Included in her “desired changes” for the current government included revising rules for new vaccines and ending “non-essential” immunizations, she said post-election on a podcast. At the FDA, Høeg has allegedly suggested barring adolescent males from receiving COVID-19 vaccines.

“She is an all-around ideologue who starts off with her conclusions and works backwards to retrofit the science in a very deceptive, untruthful fashion,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg joined fellow dissenters, {like|